Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $137.1538.
ABVX has been the topic of a number of recent analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research note on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Wedbush initiated coverage on Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price objective on the stock. Finally, Jefferies Financial Group initiated coverage on Abivax in a research note on Monday, March 16th. They issued a “buy” rating and a $160.00 price objective on the stock.
Check Out Our Latest Research Report on ABVX
Abivax Stock Performance
Abivax (NASDAQ:ABVX – Get Free Report) last announced its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts predict that Abivax will post -3.84 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Abivax
A number of hedge funds and other institutional investors have recently made changes to their positions in ABVX. UBS Group AG lifted its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares during the period. Darwin Global Management Ltd. acquired a new position in shares of Abivax in the third quarter worth approximately $263,698,000. Morgan Stanley increased its holdings in Abivax by 114.3% in the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after purchasing an additional 1,681,277 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Abivax in the third quarter worth approximately $132,800,000. Finally, TCG Crossover Management LLC increased its holdings in Abivax by 17.4% in the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares in the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.
About Abivax
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Read More
- Five stocks we like better than Abivax
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
